Q&A: Amid an M&A flurry at Charles River, longtime exec Birgit Girshick discusses how Covid-19 has changed the game

Contract research and manufacturing has been running at a rapid clip amid the pandemic, and big players in the space have looked to leverage runaway cash flow to turbocharge their business. For CRO Charles River Laboratories, that means more of everything — including a big infusion into its manufacturing arm.


Click to view original post